1
|
Zhang Q, Lin J, Yang M, Li Z, Zhang M, Bu B. Therapeutic potential of natural killer cells in neuroimmunological diseases. Biomed Pharmacother 2024; 173:116371. [PMID: 38430631 DOI: 10.1016/j.biopha.2024.116371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Revised: 02/27/2024] [Accepted: 02/28/2024] [Indexed: 03/05/2024] Open
Abstract
Natural killer (NK) cells, a major component of the innate immune system, have prominent immunoregulatory, antitumor proliferation, and antiviral activities. NK cells act as a double-edged sword with therapeutic potential in neurological autoimmunity. Emerging evidence has identified NK cells are involved in the development and progression of neuroimmunological diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, autoimmune encephalitis, Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and idiopathic inflammatory myopathy. However, the regulatory mechanisms and functional roles of NK cells are highly variable in different clinical states of neuroimmunological diseases and need to be further determined. In this review, we summarize the evidence for the heterogenic involvement of NK cells in the above conditions. Further, we describe cutting-edge NK-cell-based immunotherapy for neuroimmunological diseases in preclinical and clinical development and highlight challenges that must be overcome to fully realize the therapeutic potential of NK cells.
Collapse
Affiliation(s)
- Qing Zhang
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Jing Lin
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Mengge Yang
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Zhijun Li
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
| | - Min Zhang
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
| | - Bitao Bu
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
| |
Collapse
|
2
|
Laakso SM, Myllynen C, Strbian D, Atula S. Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy. J Neurol Sci 2021; 427:117549. [PMID: 34167051 DOI: 10.1016/j.jns.2021.117549] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 06/15/2021] [Accepted: 06/16/2021] [Indexed: 02/07/2023]
Abstract
BACKGROUND The effect of comorbidities on the prognosis of myasthenia gravis (MG) remains unclear. In particular, the role of other autoimmune diseases (AD) is controversial. METHODS In this retrospective single-center cohort study, we investigated 154 consecutive generalized thymectomized MG patients, with a mean follow-up time of 8.6 (±5.0) years post-thymectomy. Comorbidities diagnosed at any timepoint were retrieved from medical records and Charlson comorbidity index (CCI) scores were calculated. Patients were categorized into subgroups MG alone (n = 45) and MG with any comorbidity (n = 109); the latter was further categorized into MG with other ADs (n = 33) and MG with non-AD comorbidities (n = 76). The endpoints analyzed were complete stable remission (CSR), minimal need for medications, and need for in-hospital treatments. RESULTS CSR was more frequent in MG alone than in MG with any comorbidity group (26.7% vs 8.3%, p = 0.004). Minimal need for medication was reached more often in the MG alone than in the MG with non-AD comorbidities group (p = 0.047). Need for in-hospital treatments was lower in the MG alone group than in MG patients with any comorbidity (p = 0.046). Logistic regression analysis revealed that lower CCI scores increased the likelihood of CSR (p = 0.033). Lower CCI scores were more prevalent both in patients with minimal need for medication and in patients who did not need in-hospital treatments (p < 0.001). CONCLUSIONS Patients with generalized MG and comorbidities have a poorer prognosis than patients with MG alone during almost 9 years follow-up after thymectomy. AD comorbidities appeared not to translate into a higher risk compared to other comorbidities.
Collapse
|
3
|
Noda K, Yagi Y, Yokota T. Evaluation of the risk factors predicting thrombotic complications associated with intravenous immunoglobulin therapy in neuroimmunological diseases. Neurol Sci 2021; 42:5321-5326. [PMID: 33884526 DOI: 10.1007/s10072-021-05192-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 03/16/2021] [Indexed: 11/30/2022]
Abstract
Intravenous immunoglobulin (IVIg) therapy is increasingly used for various conditions that include neuroimmunological disorders, such as chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, myasthenia gravis, and myositis. Although IVIg therapy is considered a relatively safe treatment, previous studies have reported thrombotic complications associated with IVIg (TCI). The precise mechanisms and associated risk factors have not been fully elucidated to date. Three of our patients experienced TCI. Although immobility is one of the most common risk factors for venous thrombosis, all three patients could walk without assistance; their modified Rankin Scale (mRS) scores were 2. We assessed the clinical characteristics of these patients and compared their data with that of 65 patients who received IVIg from the years 2000 to 2019 without experiencing TCI to identify associated risk factors. The frequency of TCI among patients with neuroimmunological disorders at our hospital was 4.4% (3/68 patients). There were no significant differences between the patients with and without TCI regarding their mean age (69.7 vs 58.0 years, p = 0.244), percentage of females (66.7% vs 45.6%, p = 0.588), mean body mass index (22.67 vs 22.16, p = 0.878), mean mRS score (2.22 vs 2.00, p = 0.658), and use of oral prednisolone (66.7% vs 13.8%, p = 0.0658). Interestingly, the D-dimer levels of two of the patients with TCI were not elevated before treatment. Sixteen patients received anticoagulant therapy during IVIg treatment, and none suffered from TCI. As our analysis suggested, it might be important to monitor D-dimer levels before and after IVIg to help prevent and detect TCI.
Collapse
Affiliation(s)
- Kotaro Noda
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Tokyo, 113-8519, Japan
| | - Yohsuke Yagi
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Tokyo, 113-8519, Japan
| | - Takanori Yokota
- Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Tokyo, 113-8519, Japan.
| |
Collapse
|
4
|
Abstract
Our understanding of the etiology of multiple sclerosis (MS) is inadequate to effectively combat the increasing incidence and prevalence of the disease. Environmental factors are of crucial importance but more information about them is needed. Recent results of incidence trends over several decades in Denmark, Norway and Finland provide suggestions for further studies on the subject. Since incidence trends show marked differences by region and sex taking these factors into account when investigating birth cohort exposures could provide important new insights. Exposures during the first 15 years of life should be prioritized. International and multidisciplinary co-operation is needed.
Collapse
Affiliation(s)
- Jussi O T Sipilä
- Department of Neurology, Siun sote, North Karelia Central Hospital, Joensuu, Finland; Clinical Neurosciences, University of Turku, Turku, Finland.
| |
Collapse
|